<DOC>
	<DOCNO>NCT02687854</DOCNO>
	<brief_summary>To obtain good understand comparative effectiveness apixaban versus VKA ( Vitamin K antagonist ) stroke prevention patient NVAF ( Non-valvular atrial fibrillation ) real-life setting .</brief_summary>
	<brief_title>Real-world Comparative Effectiveness Apixaban Versus Vitamin K Antagonist</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>NVAF define occurrence 2 inpatient outpatient claim ICD9 427.31 diagnosis code time patient 's data history prior inclusion Patients require 180 day enrollment assessment baseline characteristic CHA2DS2Vasc ( C : Congestive heart failure ; H : Hypertension ; A2 : Age ≥75 year ; D : Diabetes mellitus ; S2 : prior Stroke TIA Thromboembolism ; V : Vascular disease ; A : Age 6574 year ; Sc : Sex category ) score ≥2 180 day prior index apixaban use baseline period Patients &lt; 18 year age Patients valvular AF ( Atrial fibrillation ) Pregnancy Malignant cancer Transient cause AF Patients VTE ( Venous thromboembolism ) ( pulmonary embolism DVT ( Deep Vein Thrombosis ) ) Patients major surgery define hip knee replacement Prescriptions OACs ( Oral anticoagulant ) ( apixaban , warfarin , dabigatran , rivaroxaban ) index date Prescription one OAC index date Patient event define composite endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation ( NVAF )</keyword>
	<keyword>Prevention</keyword>
	<keyword>Stroke</keyword>
</DOC>